Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 ...

Der Forschungsbericht des globalen HEPPS-Puffer in Reagenzienqualität-Marktes untersucht die aktuelle und zukünftige ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced a $76 million expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and ...

Merck has recently inaugurated its new 290 million-euro biosafety testing facility in Rockville, Maryland, USA with an aim to ...

The enormous size of the chemical industry could make chemical stocks attractive to many investors. Large chemical stocks to consider include Air Products & Chemicals. Smaller chemical stocks with ...

California gastroenterologist Dr. Saurabh Sethi has taken to TikTok to call out three potentially carcinogenic chemicals found in many processed foods sold in the U.S. His warning comes as more ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).